Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy

References

• National Institute for Health and Care ExcellenceType 2 Diabetes in Adults: Management2015NICE guideline (NG28) Available from: http://www.nice.org.uk/guidance/ng28?unlid=9428993482016126103832Accessed July 1, 2016
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2016Diabetes Care201639suppl 1S1S10626696671
   PubMed Web of Science ®Google Scholar
• HermanGStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther200578667568816338283
   PubMed Web of Science ®Google Scholar
• PapanasNMaltezisEMetformin: a review of its use in the treatment of type 2 diabetesClin Med Ther2009113671381
   Google Scholar
• CampbellRKClarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitusClin Ther201133551152721665040
   PubMed Web of Science ®Google Scholar
• PerfettiRHuiHThe role of GLP-1 in the life and death of pancreatic beta cellsHorm Metab Res20043611–1280481015655712
   PubMed Web of Science ®Google Scholar
• GolightlyLKDrayanaCCMcDermottMTComparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitorsClin Pharmacokinet201251850151422686547
   PubMed Web of Science ®Google Scholar
• BergenstalRMWyshamCMacConellLDURATION-2 Study GroupEfficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialLancet2010376973943143920580422
   PubMed Web of Science ®Google Scholar
• ChwiedukCMSitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitusDrugs201171334936121319871
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology InformationPubChem Compound Database; CID=4091 Available from: http://pubchem.ncbi.nlm.nih.gov/compound/4091Accessed January 2016
   Google Scholar
• National Center for Biotechnology InformationPubChem Compound Database; CID=4369359 Available from: http://pubchem.ncbi.nlm.nih.gov/compound/4369359Accessed January 2016
   Google Scholar
• HermanGABergmanAYiBKipnesMSitagliptin Study 012 GroupTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin200622101939194717022853
   PubMed Web of Science ®Google Scholar
• RazIChenYWuMEfficacy and safety of sitagliptin added to ongoing metformin in therapy in patients with type 2 diabetesCurr Med Res Opin200824253755018194595
   PubMed Web of Science ®Google Scholar
• BrazgRXuLDallaMCEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-hour glycemic control and B-cell function in patients with type 2 diabetesDiabetes Obes Metab20079218619317300594
   PubMed Web of Science ®Google Scholar
• AschnerPChanJOwensDEASIE investigatorsInsulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trialLancet201237998332262226922683131
   PubMed Web of Science ®Google Scholar
• PerfettiRHuiHThe role of GLP-1 in the life and death of pancreatic beta cellsHorm Metab Res20043611–1280481015655712
   PubMed Web of Science ®Google Scholar
• Williams-HermanDXuLTengREffect of initial combination therapy with sitagliptin and metformin on B-cell function in patients with type 2 diabetesDiabetes Obes Metab2012141677622050786
   PubMed Web of Science ®Google Scholar
• ReasnerCOlanskyLSeckTThe effect of initial therapy with the fixed–dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusDiabetes Obes Metab201113764465221410627
   PubMed Web of Science ®Google Scholar
• Williams-HermanDJohnsonJTengREfficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetesDiabetes Obes Metab201012544245120415693
   PubMed Web of Science ®Google Scholar
• GoldsteinBFeinglosMLuncefordJJohnsonJWilliams-HermanDSitagliptin 036 Study GroupEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care20073081979198717485570
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeiningerGSitagliptin Study 020 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care200629122638264317130197
   PubMed Web of Science ®Google Scholar
• NauckMMeiningerGShengDTerranellaLSteinPPSitagliptin Study 024 GroupEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab20079219420617300595
   PubMed Web of Science ®Google Scholar
• SeckTNauckMShengDSafety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInt J Clin Pract201064556257620456211
   PubMed Web of Science ®Google Scholar
• KarasikAWuMWilliams-HermanDSitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss [abstract no. 523-P (plus poster)]67th Scientific Sessions of the American Diabetes AssociationJun 22–26, 2007Chicago, ILA139
   Google Scholar
• ArechavaletaRSeckTChenYEfficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab201113216016821199268
   PubMed Web of Science ®Google Scholar
• BergenstalRFortiAChiassonJLWoloschakMBoldrinMBalenaREfficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial)Diabetes Ther2012311323138449
   PubMedGoogle Scholar
• SchernthanerGGrossJLRosenstockJCanagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trialDiabetes Care20133692508251523564919
   PubMed Web of Science ®Google Scholar
• VilsbollJRosenstockHJarvinenYEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes TDiabetes Obes Metab201012216717720092585
   PubMed Web of Science ®Google Scholar
• Januvia (sitagliptin) [package insert]Whitehouse Station, NJMerck2011 Available from: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdfAccessed December 2015
   Google Scholar
• LiLShenJBalaMIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus:systematic review and meta-analysis of randomised and non-randomised studiesBMJ2014345g236624736555
   PubMedGoogle Scholar
• GargRChenWPendergrassMAcute pancreatitis in type 2 diabetes treated with exenatide or sitagliptinDiabetes Care201033112349235420682680
   PubMed Web of Science ®Google Scholar
• HeafJMetformin in chronic kidney disease: time for a rethinkPerit Dial Int201434435335724711640
   PubMed Web of Science ®Google Scholar
• ChanJScottRArjona FerreiraJSafety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiencyDiabetes Obes Metab200810754555518518892
   PubMed Web of Science ®Google Scholar
• Joint Formulary Committee [homepage on the Internet]British National FormularyLondonBMJ Group and Pharmaceutical Available from: www.medicinescomplete.comAccessed January 2016
   Google Scholar